Tag: Flexible
Breaking News
How to Amplify Your Gains with ADA
Ever since people got the idea that it’s possible to make the crypto experience faster and better, different crypto coins have never stopped to emerge with completely various purposes. It seems that everyone in the crypto world has heard about Cardano (ADA). We are not an exception and for those of you who still know ... Read more
The post How to Amplify Your Gains with ADA first appeared on Blog.
Binance Labs Makes Strategic Investment in Solv Protocol: Next Big Leap for NFTs?
Binance Labs and Solv Protocol will collaborate on launching NFTs on the Binance NFT marketplace and on helping Binance Labs portfolio companies to grow Financial NFTs. This is a strategic move on both sides that will undoubtedly change NFTs forever. Solv Protocol is a decentralized platform for creating, managing, and on-chain trading Financial NFTs that [...]
The post Binance Labs Makes Strategic Investment in Solv Protocol: Next Big Leap for NFTs? appeared first on Blockonomi.
MATIC Technical Analysis: Price at 200-Day EMA Aims to Touch $3
The MATIC coin price aims to overcome sellers at $2.5 to regain bullish momentum and bring a bullish breakout of a long-coming resistance trendline. Polygon (previously Matic Network) is the first well-organized and user-friendly platform to support Ethereum infrastructure development and scaling. The core component of the platform is the Polygon SDK, a modular, flexible framework that can be used to build different kinds of applications. Polygon effectively converts Ethereum into a fully-fledged Multi-chain System. The multi-chain system is similar to others like Polkadot, Cosmos, Avalanche, and so on. Let us move ahead to read about Polygon technical analysis. Past Performance of MATIC The MATIC coin price shows a growth of more than 5% in the past 24 hours despite a previous higher price rejection candle. The price action maintains a sideways movement between $1.5 and $1.75. The recent long-range candles indicate increased trend volatility in the short term as buyers struggle to regain trend control. MATIC/USD Daily Chart MATIC Technical Analysis The MATIC coin price rises higher but struggles to overcome sellers at the 200-day EMA. However, the growing interest in DeFi-related coins can shortly result in a bullish recovery for Polygon. The crucial Exponential Moving Averages show increased chances of a bearish crossover of the 50 and 100-day EMA. Moreover, the struggling prices to overcome the selling pressure at the 200-day EMA fuels the consolidation range. The Stochastic RSI Indicator shows a rise in the K and D lines as they escape the oversold zone after the recent bullish crossover. Therefore, the bullish cycle might soon result in the 200-day EMA breakout. The DMI Indicator shows a sharp rise in trend momentum evident by the jump in the ADX line. The DI lines reflect a bearish trend in action, but the recent reversal increases the chances of a bullish crossover. Hence, the technical indicators reflect a bullish rise in MATIC within the consolidation range increasing the breakout possibility. Upcoming Trend The MATIC coin price jump in the past 24 hours reflects a bullish reversal within the consolidation range. However, the increased momentum increases the 200-day EMA breakout possibility. Buyers need to be patient till the prices break above the 200-day EMA before making a target at 100-day EMA or $2. At press time, TradingView keeps a “NEUTRAL” sentiment for the MATIC coin. Technical Analysis for MATICUSD
The post MATIC Technical Analysis: Price at 200-Day EMA Aims to Touch $3 appeared first on Cryptoknowmics-Crypto News and Media Platform.
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
 |
Tremendous achievements have been made through public-private partnership since the launch of the London Declaration to 2020. The pharma industry has contributed to the elimination of NTDs via supply of medicines which resulted in donation of 13 billion high-quality treatments. Forty-three countries have eliminated at least one NTD and 600 million people no longer require interventions against NTDs. Despite such progress, more than 1.7 billion people remain threatened by NTDs.
In the event, CEO Haruo Naito said, "Our initiatives toward NTDs elimination are rooted in the pharmaceutical company's fundamental mission to deliver medicines to those who need them to treat illness and save lives. While R&D for NTDs treatments have become more active after the London Declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. Utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure."
Under the London Declaration, Eisai has been manufacturing and supplying diethylcarbamazine (DEC) tablets, one of the lymphatic filariasis (LF) treatments, free of charge to the WHO for the elimination of LF. To date, 2.05 billion DEC tablets manufactured at Eisai's Vizag Plant in India have been supplied to 29 countries (as of January 2022). Although LF has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. Eisai is committed to providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries. In addition to the supply of DEC tablets, Eisai is working on various initiatives such as support for the mass drug administrations (MDA), disease awareness and improvements in sanitation.
Furthermore, Eisai is proactively engaged in development of new treatments for NTDs through partnerships with global research organizations. Utilizing the funding from the Global Health Innovative Technology Fund (GHIT Fund) and others, Eisai is conducting joint development of new treatments such as a new treatment for LF in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the Drugs for Neglected Diseases initiative (DNDi).
Eisai commits to the Kigali Declaration and strengthens collaborations with global partners to tackle NTDs towards the achievement of NTD road map 2021-2030.
Based on human health care (hhc) philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries. Once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. Eisai considers this to be a long-term investment in creating the markets for the future. Eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including NTDs and facilitate initiatives to improve access to medicine such as support for MDAs and disease awareness activities. Through these initiatives, Eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.
About Neglected Tropic Diseases (NTDs)
Neglected Tropic Diseases (NTDs) include 20 diseases that the WHO identifies as tropical diseases which human race must overcome. More than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of NTDs infection. The spread of NTDs is mainly caused by poor hygienic conditions associated with poverty. Infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. In the worst cases, NTDs may also result in death. The prevalence of NTDs is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.
The following 20 NTDs have been designated by WHO for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (Hansen's disease], Chagas disease, human African trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.
About London Declaration on Neglected Tropical Diseases
On January 30, 2012, the CEOs of 13 pharmaceutical companies*, the Bill & Melinda Gates Foundation, WHO, the U.S. Agency for International Development (USAID), the U.K. Department for International Development (DFID), the World Bank, and officials from NTD-endemic countries gathered in London to pledge their support for a coordinated effort to combat 10 NTDs**. The London Declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat NTDs.
Commemorating the London Declaration, January 30 has been designated as the World NTD Day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of NTDs. Eisai is sponsoring the light up of Tokyo Tower to raise disease awareness and disseminate the importance of eliminating NTDs.
* Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, GlaxonSmithKline, Gilead, Johnson & Johnson, Merck (Merck KGaA: Germany), Merck Sharp & Dhome, Novartis, Pfizer, Sanofi
** Guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human African trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, Chagas disease, and visceral leishmaniasis
About Kigali Declaration on Neglected Tropical Diseases
As the successor of the London Declaration on NTDs launched in 2012, the Kigali Declaration represents a collective commitment from stakeholders to fight against NTDs. With the endorsements from stakeholders being initiated at the online event entitled "100% COMMITTED to End NTDs", a campaign to commemorate the 10th year anniversary of the London Declaration held on January 27, 2022, the Kigali Declaration will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda. To achieve the WHO's NTD roadmap 2021-2030, the Kigali Declaration aims to tackle NTDs comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics for NTDs and ensuring equitable access to these NTDs related products and services.
About Lymphatic Filariasis
Lymphatic filariasis (LF) is an NTD transmitted to humans via carrier mosquitoes. LF causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. As a result, patients suffer mental, social and financial losses. It is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of LF. Elimination of LF is possible by stopping the spread of the infection through MDAs of three types of LF treatments including DEC tablets.
About Eisai's Commitment to Improving Global Access to Medicines including LF Elimination Program
In line with its hhc philosophy, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.
In November 2010, Eisai agreed to supply a total of 2.2 billion DEC tablets to the WHO free of charge by 2020, as there was a global shortage of high-quality DEC tablets for use in MDAs. In 2012, Eisai became the only Japanese company to participate in the London Declaration, a coordinated effort to eliminate 10 NTDs and the largest public-private partnership of its kind in the field of global health. At the London Declaration's fifth anniversary event held in April 2017, Eisai announced its plan to supply DEC tablets continuously beyond 2020, until LF is eliminated in all endemic countries where DEC tablets are needed.
Eisai has supplied 2.05 billion tablets to 29 countries through the WHO's elimination program (as of January 2022). Furthermore, in order to support the smooth implementation of the WHO's MDA programs, Eisai is engaging in initiatives to raise public awareness of LF in endemic countries. Staff members of Eisai Group cooperate with the relevant representatives in endemic countries to eliminate LF as early as possible.
In addition to the above-mentioned initiatives, Eisai is moving ahead with new drug development projects targeting malaria and NTDs such as mycetoma and LF, based on partnerships with international non-profit organizations such as the Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV), as well as research organizations such as Liverpool School of Tropical Medicine, University of Kentucky, and the Broad Institute (please refer to the table above).
Furthermore, Eisai co-established the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public-private partnership to advance development of new health technologies for the developing world, is a member of the World Intellectual Property Organization (WIPO) Re:Search Consortium, an international joint enterprise for the development of treatments for NTDs, malaria and tuberculosis led by WIPO, is a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, and is participating in the Access Accelerated initiative to promote prevention and treatment of non-communicable diseases.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022.
Pakistan’s Silkbank Taps Silverlake Axis to Grow its Credit Card Footprint
 |
OmniCard V6 is an internationally certified card management system that allows banks to run flexible and secure operations including issuing and acquiring of all types of credit, debit and prepaid cards, ATM management, 3D secure e-commerce transaction processing, management of fraud, disputes, and cardholder's loyalty. This latest move also strengthens Silverlake's leadership position within Pakistan's credit card market, where it currently commands an 80 percent market share. It also allows Pakistan's and the region's banks to tap into Silverlake's award winning technologies to grow their card footprints, and in the process better cater to customers.
Gyorgy Ladics, CEO of Silverlake Symmetri, commented: "We are immensely proud of the deep and long-standing partnership we have forged with Silkbank. Pakistan continues to establish itself as a fast-growing market, with huge potential for building its credit card market, and we are very optimistic about its growth. To that end, the trust Silkbank has placed in us is a true honor, and as we continue this exciting journey together, we are confident that this trust will see strong returns."
Nabeel Malik, Executive Director, Strategy Implementation & Ops/Admin/IT/CSQ at Silkbank, commented: "Silkbank always aims to stay ahead of the market by introducing unique products supported by latest technological tools. Silverlake has been a trusted partner to Silkbank for 9 years. As we continue to transform and advance the banking landscape in Pakistan with our innovative product offerings and best-in-class services, the in-depth experience, system understanding, and professionalism of Silverlake team will be a key factor for us to grow with confidence. We hope that we will be continuing this beneficial partnership in years to come."
With over 30 years of experience across industries, Silverlake creates technologies to empower businesses in the digital economy, transforming industries like banking, insurance, retail, and logistics. Silverlake Symmetri OmniCard is a universal card and payment management system, designed to help both acquiring and issuing institutions to run efficient, secure and profitable operations. Banks can reduce time to market for new card products while at the same time offer excellent service to drive loyalty across the customer base. The solution also enables them to cross-sell and up-sell, while reducing fraud and risk, and ensuring regulatory compliance.
"With Silverlake Axis already issuing 80% of cards in the market, Silkbank's partnership to deploy our credit card solutions only solidifies our leadership position in Pakistan. However, it's only one step in our growth plan. We are seeing strong opportunities across the MENA, South and Southeast Asia regions with our Islamic and retail banking partners as well," added Ladics.
About Silverlake Axis
Silverlake Axis Ltd. (SLVX.SI; SILV:SP) is a leading enterprise technology, software and services company focused on financial services and serving 40% of the top 20 largest banks in South East Asia. Founded in 1989, Silverlake has an impeccable track record of successful delivery of innovative and transformative solutions to its enterprise customers and their ecosystems. The Group has more than 380 enterprise customers in over 80 countries across Asia, Europe, Middle East, Africa and the Americas.
Silverlake Axis was listed on the Singapore Exchange (SGX) Catalist in 2003 and moved to the SGX Mainboard in 2011. For more information, please visit https://www.silverlakeaxis.com.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSGX-listed Silverlake Axis Ltd (SGX:5CP), the ASEAN leader in core banking systems and solutions, today announced an expansion of its partnership with Silkbank, a leading commercial and Islamic bank in Pakistan. Through the latest agreement, Silkbank will upgrade its card management suite to use Silverlake's latest platform, Symmetri OmniCard V6.
Tons of New Magic Leap 2 Details Shed Light on Dynamic Dimming & More
Although it’s expected to launch this year, there’s still no firm release date on Magic Leap 2. However, the company has begun sharing details on the headset which suggests the launch is approaching. This week at the SPIE Photonics West 2022 conference, Magic Leap’s VP of Optical Engineering, Kevin Curtis, took to the stage to […]
The post Tons of New Magic Leap 2 Details Shed Light on Dynamic Dimming & More appeared first on Road to VR.
Cake Monster Launches a Monster Supply Burn for Its $MONSTA Token
The reserve is generated from a small transaction and proof of life tax (once every fifty days.) This ensures the continual and fair hyper-deflation of the total $MONSTA supply. The reserve is growing fast, with average monthly APYs well over 500% and over 188K $CAKE already in the vault. Over TWENTY percent (20%) of the total supply has been burned, amounting to over two billion $MONSTA tokens. This is an extraordinary achievement for a new protocol in the current market in such a small amount of time.
The Monster Supply Burn
With just under a year and a half to go until the end of the first cycle, the ongoing hyper-deflation (token supply burn) seems likely to make things very hot, driving the price of $MONSTA up as the supply shrinks. This, in turn, will increase the growth rate of the reserve and further increase demand for $MONSTA, potentially a volcanically virtuous cycle for token holders.
However, the platform does not stop there as the supply is also elastic. Once the first cycle is complete and the reserve contents are distributed to $MONSTA holders, a new cycle is triggered, and previous cycle holders will be reissued their $MONSTA. The re-issuance will be in proportion to their percentage of holdings at the end of the previous cycle. The heart of the protocol beats again; the hyper-deflation and reserve growth begin anew with remaining liquidity from cycle one added to the news cycle.
The Cake Monster platform is replete with incentives to earn, explore and have fun. Already deployed are; Crumbs, Kitchen Making, Cashout of inactive accounts, Diamond Claw NFTs, and the Monsta Party NFT and P2E platform (first to be launched and generated while in outer space... the video is extraordinary.)
About the $MONSTA Token
The monster token is a BEP-20 compliant token used within the Cake Monster ecosystem. The initial supply of the token is 10 billion. However, as a result of the monster burn, the final supply will be 1 million (0.1%) of the initial token supply. For the token distribution, 30% of the tokens will be utilized for community engagement, marketing, and airdrop, 10% for the team, 50% presale, and 10% for public sale.
Innovative Features of the Monster Ecosystem
- Single-sided $MONSTA staking
Once deployed, $MONSTA holders will be rewarded for their commitment, which may positively affect the market and growth rate of the reserve. The potential for centralized exchange listing is also increased due to simple technical solutions to the transaction tax being possible.
- Lottery
More than one lottery is under development but the first to be released is something the team dubbed "Eternal CAKE."
The Eternal CAKE lottery will enable active diamond claw NFT holders to mint a lottery ticket. The numbers will be drawn every three days. If a player wins, they will be able to claim their prize. If nobody wins, or the winner doesn't claim their prize, the $CAKE is added back to the pot for the next prize draw. This means the opportunity for some potentially juicy and large jackpots to be won.
Once you have minted (or purchased later from a marketplace) a lottery ticket, it never expires. In other words, it provides the owner with ongoing access to all future Eternal CAKE lottery draws.
- Rob-a-Monsta
This new addition to the Monsta Party NFT platform is a protocol feature called "Rob A Monsta" (RAM). It is a P2E (play 2 earn) game that will reward active Monsta Party players at the expense of inactive players.
All-Party Monstas that have ever been fed by their owner continually accrue $MONSTA dividends, even if never fed again. However, active players (those feeding their Party Monstas) will be able to claim any pending $MONSTA dividends for Party Monstas not being fed by initiating a "robbery."
- Multi-asset vault
After a recent vote of community members, which returned an overwhelmingly positive result in favor, a new reserve asset (BNB) will be added to the protocol, making it multi-asset. This is expected to provide significant additional resiliency and further collaboration and community growth opportunities.
About Cake Monster
Cake Monster ($MONSTA) offers a multitude of great features aimed at building a flexible, multifaceted, and automated dividend yield and reward system for participants without compromising the sustainability or security of the protocol ecosystem, and combines this with smart design, creativity, and organic growth, resulting in a very vibrant and engaged community.
Cake Monster may look like a meme at first glance, but behind the stunning artwork and fun, whimsical nature is an economic model with significant and powerful innovation. It has attracted many knowledgeable minds and a passionate and engaged community. Innovation within the project is rapidly accelerating, with incoming developments and deployments representing only a small part of what is to come. An incredibly comprehensive and efficient PR and marketing campaign strategy has been developed to maximize awareness, growth potential, discussion, education, and utility of the core protocol and all future deployments. With these building blocks and ambition to match, this project is worthy of attention and deep analysis.
About Cake Monster
Cake Monster ($MONSTA), a DeFi protocol on Binance Smart chain, offers unique features focused on developing a flexible, multifaceted, and automated dividend yield and reward system for participants. It's the first protocol to design an increasing Gravity Vault CAKE Reserve that opens up to all $MONSTA holders and rewards them with $CAKE.
For more information, visit
Website: https://cake.monster/
Twitter: https://twitter.com/MonstaPartyNFTs
Telegram: https://t.me/cakemnstr
Reddit: https://www.reddit.com/r/CAKEMONSTER/
Medium: https://cakemonster.medium.com/
Media Queries
Byron James, Cake Monster Media Office
Email: [email protected]r
SOURCE: Cake Monster
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comCake Monster, a new decentralized finance (DeFi) protocol on the Binance Smart Chain (BSC), has announced a revolutionary supply burn for its token.
Latest Intelligence
